Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: prometheusbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/10/2023 | $160.00 → $200.00 | Buy → Hold | Jefferies |
| 7/20/2022 | $51.00 | Buy | Goldman |
| 6/10/2022 | $53.00 | Overweight | Piper Sandler |
| 3/10/2022 | $50.00 → $52.00 | Outperform | Credit Suisse |
| 3/10/2022 | $42.00 → $53.00 | Overweight | Wells Fargo |
| 3/10/2022 | $47.00 → $55.00 | Outperform | SVB Leerink |
| 2/11/2022 | $62.00 | Buy | BTIG |
| 12/13/2021 | $46.00 | Outperform | RBC Capital Mkts |
| 12/8/2021 | $42.00 | Overweight | Wells Fargo |
| 12/8/2021 | $35.00 → $50.00 | Perform → Outperform | Oppenheimer |